INNOVATE • INTERACT • INVEST
Cancer Progress Conference 2022 Panels
How to Catch and Treat Cancer Early
State of the Art in Immuno-Oncology: Beyond PDx Inhibitors – or Not So Much
The Latest Potential “Paradigm-Shifters”
Biotech Corporate Strategy: Inflecting Value - Partnering Versus Go It Alone
What’s Hot/What’s Not for Startups in the Quasi-Post-Pandemic Oncology World?
Biotech versus Pharma Perspectives - Clinical Development Strategy
Degraders & Beyond: The Rise of Diverse Heterobifunctional Molecules
Into the Unknown – Bringing New Modalities into Solid Tumors
Growing Pains - Navigating the Precipitous Path Towards Commercialization
Tortoises and Hares - De-risking Strategies Towards Multiplexed Candidates
Selling the Cell - Cost-benefit Considerations for Complex Therapeutics
Battle of the Modalities: The Sequel to the Sequel - Revenge of the Nerds
Since 1989, Cancer Progress is the only oncology conference that facilitates discussions of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives over three days of provocative, informative panel discussions. The conference will feature pivotal topics, frank discussions, vigorous debate, opportunities for audience questions and comments, and a partnering platform to enable meaningful connections and meetings with innovators, developers and investors.
Our 34th Annual Meeting on May 2-3, 2023, will provide an unsurpassed learning experience for participants in quality of information, coverage of issues, and value of professional contacts. The quality of the speaking faculty is a major contributor to the popularity and value of this conference.
Testimonials
Good array of opinions and technologies. Well curated
Andrew Allen, MD, PhD, President & CEO
Gritstone OncologyAs I like to say, Cancer Progress is THE BEST non-academic cancer conference out there. Again proving your staggering insight!
Michael G. King, Jr., Entrepreneur in Residence
Fortress Biotech Inc.When we hear all the negatives from the experts on cell therapies and COVID—let’s think of Richard Feynman: “Science is the belief in the ignorance of the experts
Mark Simon, Managing Director
Torreya“Thank you for the opportunity. I felt privileged to be part of a panel composed of stellar leaders within the Oncology space.”
Noemi Rosa
Novartis“I really enjoyed the meeting as usual – great topics and speakers. I look forward to next year’s meeting!”